1 / 36

Buprenorphine

Buprenorphine. Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center. Buprenorphine: Outline. Brief historical background Methadone maintenance treatment Buprenorphine: characteristics and efficacy Buprenorphine in Washington State. U.S. Epidemiology and Costs.

adli
Download Presentation

Buprenorphine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center

  2. Buprenorphine: Outline • Brief historical background • Methadone maintenance treatment • Buprenorphine: characteristics and efficacy • Buprenorphine in Washington State

  3. U.S. Epidemiology and Costs • 980,000 opiate-dependent persons • Over 200,000 in methadone treatment • “Problem use” increasing • Emergency visits, crime, opiate-related deaths • Costs to society $20 billion • Health care costs $1.2 billion

  4. King County • 12-15,000 opiate-dependent persons • 2% HIV prevalence • >90% Hepatitis C prevalence • 1.5% annual overdose deaths

  5. King County: Heroin-Related Deaths

  6. Heroin CostAverage Amount Available for $100 Bach & Lantos, 1999

  7. Historical Perspective • 1910’s – 1960’s • Physicians excluded from addiction treatment • High relapse rates • 1960’s – 1970’s • Increased heroin use and crime • Introduction of methadone maintenance

  8. First Randomized TrialDole et al - 1969 • Imprisoned and dependent > 4 years (N=32)

  9. Addiction as a Brain Disease • Prolonged drug use changes brain function • Changes are pervasive and persist after drug use stops • Brain changes demonstrated at many levels • Molecular • Cellular • Structural • Functional

  10. Methadone Maintenance:Expansion and Regulation • Rapid expansion to reduce crime • 400 patients in 1968 to 73,000 in 1973 • Program quality inconsistent • Fear of methadone “diversion” • Regulation of methadone • Controlled Substances Act • FDA, DEA and state oversight • Physicians cannot prescribe for addiction

  11. Methadone Maintenance:Treatment Outcomes • Methadone: • Reduces overall and overdose deaths • Drug use • Criminal behavior • Spread of infectious diseases (HIV, TB) • Not a cure

  12. Frequency of Heroin Use & Methadone Dose Level Past month IV drug use (%) Adapted from V. Dole (1989) JAMA, 282, p. 1881

  13. Reduction of Heroin Use By Duration of Methadone Treatment Pre- treatment Admission: < 6 months stay Average Stay: 6 to 54 months Long-term: > 54 months Adapted from: Ball & Ross, 1991.

  14. Return to I.V. Drug Use Following Termination of Methadone Treatment % IV USERS Months Since Dropout Adapted from: Ball & Ross, 1991.

  15. Methadone Maintenance:How Long? • Randomized trial of 179 patients • Maintenance versus 180-day psychosocially enriched detoxification • Maintenance resulted in greater treatment retention and less heroin use • No support for diverting resources from maintenance to long-term detoxification JAMA 2000;283:1303-10

  16. Methadone Maintenance:Limitations • Highly structured program (6 days/week) • Limited clinical flexibility • Minimal medical services • Expansion often opposed • Treatment access limited • Stigma

  17. Methadone Maintenance Policy • Policy Progress • Expansion of “medical maintenance” • Regulatory change to accreditation model • Policy Limitations • Medical maintenance applies to few patients • Initiation of methadone in physician practices not yet approved

  18. Buprenorphine:New Office-Based Option? • Partial opiate agonist • Less overdose potential • Less physical dependence • Binds mu-receptor strongly • Buprenorphine pharmacokinetics • Not absorbed PO; given SL • Slow onset, long duration • Once a day or every other day dosing

  19. Full Agonist vs Partial Agonist 100 90 Full Agonist 80 70 Activity 60 Partial Agonist 50 40 30 20 Antagonist 10 0 -10 -9 -8 -7 -6 -5 -4 Log Dose of Opioid

  20. Buprenorphine • Comparable to methadone in most studies • With naloxone, reduced abuse potential • Advocated for physician-based practice • Good candidate for initial opiate therapy • Being studied as a detoxification agent • Now FDA approved for addiction treatment

  21. Buprenorphine Efficacy • RCT of 40 Swedish patients ineligible for methadone but >1 year of dependence • Control group given buprenorphine taper (1 week) • Both groups given weekly CBT • One-year outcomes: • Treatment retention 75% vs 0% • 75% urine test negative in buprenorphine group • Addiction severity improved over time • Mortality benefit in small sample (p=0.015)

  22. Drug Addiction Treatment Act: October 2000 • Amends the Controlled Substances Act • Allows Schedule III-V drugs approved for addiction to be used by MDs outside Opiate Treatment Programs • Requires MD training and registration • MD must have psychosocial referral capacity • Limits any group practice to 30 patients

  23. Buprenorphine in France • Permitted for addiction treatment since 1996 • Limited oversight of generalist physicians • Estimated 67-89,000 patients by 2000 • Lessons: • Generally good treatment retention • Overdose deaths rare (associated with benzos) • Abuse/IV use of sublingual tablets documented

  24. Challenges for Buprenorphine • Current and potential future Federal limitations • Training for physicians • Integration of medical and addiction services • Confidentiality of drug treatment records • How to pay for it!

  25. Buprenorphine in WA State • Facilitate and evaluate the development and implementation of a pilot office-based buprenorphine program within the Washington State Medicaid program • Funded by the RWJ Substance Abuse Policy Research Program

  26. Research Aims • To document the policy and protocol development of a public-sector buprenorphine program • To implement and evaluate a physician training and clinical support program • To evaluate the feasibility and outcomes of a pilot Medicaid buprenorphine program

  27. Policy and Protocol Development • Key Collaborating Agencies • WA State Division of Alcohol and Substance Abuse • Medical Assistance Administration (Medicaid) • Harborview Medical Center • Evergreen Treatment Services

  28. Policy and Protocol Development • Key Policy Issues • Financing of medical, pharmacy, addiction counseling services • MD recruitment, licensing, training, monitoring • Clinical Protocols • Visit requirements and take-home doses • Urine testing and responding to continued use • Diversion control and call-backs

  29. Physician Training • Federal requirements • 8-hour training • ASAM training course May, 2003 • Ongoing clinical support • Evaluation • Satisfaction with training, support, clinical care • Attitudes

  30. Pilot Program Evaluation • To understand the effects of a policy of public funding for buprenorphine treatment • 100 Medicaid patients (not managed care) • Randomized to immediate vs delayed office-based buprenorphine • All patients followed for one year after randomization

  31. Patient Measures • Collected at baseline, 3, 6, 9 and 12 months • Addiction Severity Index • Service Use • Medical, criminal justice, travel, etc. • Other • HIV risk, treatment preferences, satisfaction • Urine toxicology

  32. Buprenorphine in WA State:Summary • Key opportunity to expand access to opiate addiction treatment • Develop the financial policy and clinical protocols linking medical and addiction treatment • Provide preliminary cost and outcome data for office-based buprenorphine treatment

  33. Current Issues • Psychosocial services funding • State budget crisis • King County commitment • Medicaid limitations on pharmacy benefit (Draft) • Requires participation in state drug treatment program • Limited duration of treatment • Physician recruitment • Coordination of medical and addiction services

  34. Buprenorphine: Where To Get It? • Self-pay or insured: • Buprenorphine physician locator • Few physicians with limited treatment slots • Public Funding: • Only for GAX or CNP coupons (not GAU) • May be unavailable outside pilot program • Now permitted in Opioid Treatment Programs

  35. Summary • Buprenorphine has potential to expand treatment access and physician involvement in addiction treatment • Substantial limitations exist, especially regulatory restrictions and cost • Methadone maintenance remains a major treatment option

  36. To Learn More:buprenorphine.samhsa.gov

More Related